P-45 EVALUATION OF THE ALBI SCORE IN PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH YTTRIUM-90 (90Y)

Stefanny Cornejo,Yailin Fabiola Velazquez,Blanca Zapote,Itzia Verduzco,Erika Santiago,Salvador Amezquita,Juan Salvador Garcia,Miguel Angel Mendoza,Eira Cerda

DOI: https://doi.org/10.1016/j.aohep.2023.101232

IF: 3.388

2024-02-01

Annals of Hepatology

Abstract:Introduction and Objectives Hepatocellular carcinoma (HCC) is the third cause of mortality worldwide. 10% of patients receive therapy with curative intent. There are loco-regional therapies to improve patient survival, such as (TACE) and radioembolization with Yttrium-90. There are prognostic scales, such as ALBI, to identify who will have a positive response to the treatment. We aimed to evaluate the potential of the ALBI index for HCC as a predictor of mortality and associate it with survival or complications in patients who received treatment with Yttrium-90, correlating with Child Pugh, MELD and MELD-NA scores. Materials and Methods 8 patients with cirrhosis and (HCC) were evaluated; 60% (4) women aged 50 ±12.5 years, Child Pugh 7 points, MELD 11, MELD-NA 11, MELD 3.0 12 and initial BCLC (B), received an average of 2 radioembolization sessions with (90Y) and ALBI was evaluated. Results 3 patients had a complete response, one with intolerance to the (90Y) who required a second line of treatment. The other patients presented progression of the disease, therefore, palliative treatment and complications treating the CHC were applied. 3 patients died, who obtained an ALBI score of .08 ± 0.27 (grade 3), which could be correlated with patient survival. After Yttrium- 90, the following final values were measured Child Pugh (8.86 ±2.61), MELD (15.43±7.13), Leukocytes (6.7±1.5), Hemoglobin (12.85±1.66), Platelets (76.71±42.16), Bilirubin (4.16 ±4.58), Albumin (2.58 ±0.55) without any significant difference.The only difference was in MELD-Na (17.43 ± 6.90) which can be due to the progression and complications of the cirrhosis itself. (Table 1) Conclusions The ALBI, Child-Pugh and MELD NA scores in the prediction of mortality, survival and complications development during the disease in patients’ treatment with Yttrium-90 could be a prognostic factor. Studies with a larger group of patients are needed to correlate and obtain more significant results regarding the score of ALBI.

gastroenterology & hepatology